Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

Panelists discuss time to progression by organ with lenvatinib plus + pembrolizumab in advanced renal cell carcinoma (RCC), highlighting key data and its the implications for treatment decisions.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.1L Treatment Landscape for Advanced Renal Cell Carcinoma

EP: 2.Metastatic Site–Specific Outcomes With 1L ccRCC Therapies

EP: 3.Clinical Decision-making With TKI-IO Combinations for Advanced RCC

EP: 4.Phase 3 CLEAR Trial: Evaluating Organ-Specific Progression Patterns

Now Viewing

EP: 5.Time to Progression by Organ with Lenvatinib Plus + Pembrolizumab in Advanced RCC.

EP: 6.CLEAR Follow-Uup Analysis: Implications for Clinical Decision MakingDecision-Making

EP: 7.Future Directions in Advanced RCC

Recent Videos

Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making

Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions

MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer

Second-Line Treatment for Gastric Adenocarcinoma

Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches

Gastric Adenocarcinoma: Current Treatment Landscape

Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW

Esophageal/Gastric Adenocarcinoma Standard of Care

BESPOKE: Study Design, Efficacy End Points and Methods